The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
Adam M. Brufsky
No relevant relationships to disclose
Sara A. Hurvitz
Research Funding - Genentech/Roche
Edith A. Perez
No relevant relationships to disclose
Hideharu Yamamoto
Employment or Leadership Position - Genentech
Vicente Valero
Consultant or Advisory Role - Genentech; Roche
Research Funding - Genentech; Roche
Vincent O'Neill
Employment or Leadership Position - Genentech
Hope S. Rugo
Research Funding - Genentech; GlaxoSmithKline